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ABSTRACT
TopBP1 is a scaffold protein that coordinates acti-
vation of the DNA-damage-checkpoint response by
coupling binding of the 9-1-1 checkpoint clamp at
sites of ssDNA, to activation of the ATR–ATRIP
checkpoint kinase complex. We have now
determined the crystal structure of the N-terminal
region of human TopBP1, revealing an unexpected
triple-BRCT domain structure. The arrangement of
the BRCT domains differs significantly from previ-
ously described tandem BRCT domain structures,
and presents two distinct sites for binding
phosphopeptides in the second and third BRCT
domains. We show that the site in the second but
not third BRCT domain in the N-terminus of TopBP1,
provides specific interaction with a phosphorylated
motif at pSer387 in Rad9, which can be generated
by CK2.
INTRODUCTION
Activation of the Chk1 arm of the DNA-damage check-
point response is triggered by assembly of a number of
multiprotein complexes at segments of single-stranded
DNA resulting from replication fork stalling or from re-
section of a double-strand break (1). Multiple copies
of replication protein A, coat the single-strand DNA,
and facilitate recruitment of ATR via interaction with
its constitutive binding partner ATRIP (2). The
Rad9-Rad1-Hus1 DNA-damage checkpoint clamp is
loaded at the junction of single- and double-stranded
DNA by a specialized form of the RFC clamp loader,
incorporating Rad17 in place of Rfc1 (3,4). While there
may be some direct interaction, at least in yeast (5),
coupling of these two major complexes into a functional
system is performed by TopBP1, which binds
simultaneously to the phosphorylated C-terminal tail
of Rad9 (6–8), and to the ATR–ATRIP complex,
upregulating its kinase activity (9,10).
TopBP1 was originally identiﬁed as a binding partner of
DNA topoisomerase II in yeast 2-hybrid experiments (11),
and in addition to its involvement in the DNA-damage
checkpoint, it has been variously found to interact with
transcription factors such as Miz-1, HPV16E2 and E2F1
(12–14), the protein kinase c-Abl (15), the DNA-damage
sensor PARP-1 (16), replication protein Cdc45 (17), p53
(18) and the Nbs1 subunit of the MRN complex (19).
Recently, TopBP1 has also been implicated in recruitment
of DNA Pol-a, suggesting a role in the restart of stalled
replication forks (20), although whether this involves a
direct interaction is not clear.
Structurally, TopBP1 contains multiple copies of the
BRCT domain, ﬁrst identiﬁed in Schizosaccharomyces
pombe Rad4 (21,22) and subsequently in the C-terminal
region of the breast-cancer-associated DNA-damage
mediator protein BRCA1 (23,24). Indeed S. pombe Rad4
(aka Cut5) is the orthologue of metazoan TopBP1. In
Xenopus, binding of TopBP1 to the phosphorylated
C-terminal tail of Rad9 has been shown to be dependent
on the ﬁrst-tandem pair of BRCT domains (BRCT1:2)
(25). The TopBP1 orthologues Rad4 in S.pombe and
Dpb11 in Saccharomyces cerevisiae also interact in a
phosphorylation-dependent manner with the tail of
Rad9 and Ddc1, respectively, but in these organisms it is
the second-tandem pair of BRCT domains, BRCT3:4 that
mediate this interaction (26–28). The ﬁrst pair of BRCT
domains on Rad4 is instead involved in interaction with a
phosphorylated site in the N-terminus of Crb2, the
S. pombe homologue of mammalian 53BP1 (29,30).
Interaction of metazoan TopBP1 with ATR–ATRIP is
mediated by a speciﬁc C-terminal domain of unknown
structure, mapping between the sixth- and seventh-
BRCT domains in the protein sequence (10), which inter-
acts with conserved domains in ATR and ATRIP (9).
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A functionally comparable ATR-activating domain has
also been identiﬁed in the budding yeast equivalent of
TopBP1, Dpb11, at the C-terminus beyond the fourth
BRCT domain (31,32).
Of the remaining BRCT domains in TopBP1, BRCT6 is
implicated in binding to E2F1 (12) and PARP-1 (16),
while BRCT domains 7 and 8 mediate interaction with
the helicase BACH1/FANCJ (33). Although the basis of
these interactions remains to be described, structural
analysis of TopBP1-BRCT6 (34) suggests that it does
not involve a phospho-peptide interaction of the type
commonly mediated by tandem pairs of BRCT domains
(35–37). A clear role for the tandem-pair BRCT4:5 have
not yet emerged.
To try and gain some insight into the speciﬁc roles of
the individual domains of TopBP1 in mediating speciﬁc
protein interactions, we have now determined the crystal
structure of an N-terminal segment of human TopBP1,
from the N-terminus to beyond BRCT2 and analysed its
interactions with the C-terminal tail of Rad9 in vitro.
MATERIALS AND METHODS
Cloning, expression and puriﬁcation
Human TopBP1(1–290). DNA-encoding amino acids
1–290 of human TopBP1 was ampliﬁed by PCR from
IMAGE CLONE 8991925 (Geneservice, Cambridge,
UK), then sub-cloned into both an in-house modiﬁed
pOPIN vector (38) and pGEX-6P-1 (GE Healthcare,
Chalfont St Giles, UK) encoding N-terminal,
3C-protease cleavable, octa-histidine (His8) or
Glutathione S-Transferase (GST) afﬁnity tags,
respectively.
His8- or GST-tagged TopBP1(1–290) was transformed
into Escherichia coli expression strain Rosetta2(DE3)
pLysS (Merck, KGaA, Damstadt, Germany). A single
transformed colony was used to inoculate a 250-ml ﬂask
containing 100ml of Luria–Bertani broth (LB) supple-
mented with carbenicillin (100mg/ml) and chlorampheni-
col (34 mg/ml). The inoculated culture was grown
overnight at 37C, at 220 rpm, in an orbital shaking
incubator.
The following day, 20ml of the overnight culture was
used to inoculate a 2-l ﬂask containing 1 l of LB, supple-
mented with antibiotics as before. Cultures were grown at
37C, 220 rpm, until the optical density at 600 nm reached
0.6–0.8. They were then removed from the incubator, and
rapidly cooled on ice for 30min. Recombinant protein
expression was induced by the addition of 0.4mM
Isopropyl b-D-1-thiogalactopyranoside (IPTG), and the
cultures incubated for a further 16 h, at 220 rpm, at a
reduced temperature of 16C. Cells were then harvested
by centrifugation, and the resulting pellet stored at 80C
until required.
The cell pellet arising from 6 l of culture was resus-
pended in 100ml of 25mM HEPES pH 7.5, 1M NaCl,
5% v/v glycerol, 0.1% v/v Tween 20, supplemented with
protease inhibitors (Roche, Burgess Hill, UK), then lysed
by sonication (18 5 s bursts, on ice, at 50% amplitude,
Jencons Ultrasonic Processor). Cell debris and
precipitated material was removed by high-speed centrifu-
gation at 48 834g for 60min.
The supernatant arising from this step was applied to a
batch/gravity column containing 10ml of either Talon
(TaKaRa Bio, Saint-Germaine-en-Laye, France) or
Glutathione Sepharose 4 Fast Flow (GE Healthcare)
resin, depending on the encoded afﬁnity tag.
The column containing the cell extract and resin was
rotated/rolled at 4C for a period of 1 h to facilitate
protein binding, and then allowed to pack under gravity
ﬂow.
For the His-tagged protein, the column was washed
with 250ml of 25mM HEPES pH 7.5, 1M NaCl, 5% v/
v glycerol, 5mM imidazole. Bound protein was then
eluted with the application of 25mM HEPES pH 7.5,
1M NaCl, 5% v/v glycerol, 400mM imidazole.
Rhinovirus 3C-protease (PreScission, GE Healthcare)
was added to the eluate, and incubated overnight at 4C
to cleave the afﬁnity tag.
For the GST-tagged protein, the column was instead
washed with 250ml of 25mM HEPES pH 7.5, 1M
NaCl, 5% v/v glycerol. Rhinovirus 3C-protease was then
added directly to the resin/buffer slurry and incubated
overnight, with rolling, at 4C to cleave the afﬁnity tag.
The released protein was collected by repacking the
column under gravity ﬂow, and then collecting the eluate.
In both cases, the eluted TopBP1 (1–290) protein was
concentrated to a ﬁnal volume of 5ml (Vivaspin 20, 10 kD
MWCO, Sartorius Stedim, Epsom, UK) then applied to a
HiLoad Superdex 200 16/60 size exclusion chromatog-
raphy column (GE Healthcare) pre-equilibrated in
25mM HEPES pH 7.5, 1M NaCl, 5mM EDTA, 10mM
DTT and 5% v/v glycerol (for crystallographic studies), or
25mM HEPES pH 7.5, 100mM NaCl, 5mM EDTA,
10mM DTT and 5% v/v glycerol (for peptide-binding
studies).
Human Rad9Tail. DNA encoding the C-terminus of
human Rad9 (amino acids 264–391) was ampliﬁed by
PCR from a vector encoding full-length human Rad9
kindly provided by Dr Andrew Dore´ (ICR; The Institute
of Cancer Research, UK) then sub-cloned into the expres-
sion vector pGEX-6P-1 (GE Healthcare).
Expression and puriﬁcation of GST-Rad9Tail was es-
sentially as that described for TopBP1(1–290) except that
the cell pellet resulting from 4 l of cell culture was used to
produce the initial cell lysate, only 5ml of Glutathione
Sepharose 4 FF resin was used in the afﬁnity capture
step, and the protein was eluted from the column using
25mM HEPES pH 7.5, 1M NaCl, 10mM DTT, 5% v/v
glycerol, 5mM EDTA and 40mM reduced glutathione
and not cleaved with Rhinovirus 3C-protease.
Selenomethionine-labelled TopBP1(1–290). The
TopBP1(1–290) expression plasmid was co-transformed
along with the pRARE plasmid (Merck) into the methio-
nine auxotroph, Escherichia coli strain, B834(DE3)
(Merck). Transformed colonies were selected on LB agar
plates supplemented with antibiotics as before. From an
overnight culture, 25ml was used to inoculate a 2-l ﬂask,
containing 1 l of SelenoMet Medium Base plus Nutrient
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Mix and SelenoMethionine solution (Molecular
Dimensions, Newmarket, UK) supplemented with anti-
biotics. Cultures were incubated at 37C, 220 rpm, in an
orbital-shaking incubator, until they reached an optical
density of 0.7 at 600 nm, when they were removed
from the incubator and rapidly cooled on ice. Protein ex-
pression was induced with IPTG as before, and cultures
incubated for a further 16 h, at 220 rpm and 16C, before
the cells were harvested by centrifugation.
Incorporation of the selenomethionine label was
veriﬁed using mass spectrometry (Dr WJ Mawby,
Department of Biochemistry, University of Bristol).
Crystallization, data collection, phasing, model building
and reﬁnement
Selenomethionine-labelled TopBP1(1–290)was crystallized
at 14C using the hanging drop vapour diffusion method,
by mixing equal volumes of the protein (10–15mg/ml) with
either 100mM Tris–HCl pH 7.5, 400mMMgCl2, 20–30%
w/v polyethylene glycol 4000, 2–6% v/v glycerol
(spacegroup P21), or 100mM Tris–HCl pH 6.8, 500mM
KI, 18–25%w/v PEG 3350, 2–8% v/v glycerol (spacegroup
P213). Crystals were visible after 24 h, but generally took a
week to reach their maximum size.
Cryoprotection, for data collection, was achieved by
step-wise soaking in buffers containing increasing
amounts of glycerol, to a ﬁnal concentration of 30% v/v.
All diffraction data were collected at 100K on station
ID14.4 of the European Synchrotron Radiation Facility
(ESRF),Grenoble, France.Datawere processed and scaled
using the software packageMosﬂm (39) andScala (40).
Phases were calculated from a two-wavelength anomal-
ous dispersion experiment with the P213 crystals, which
comprised one molecule per asymmetric unit and a
solvent content of 68%. Positions of eight Se atoms and
ﬁve Iodide ions could be determined using SHELX (41)
and reﬁned using SHARP (42), yielding an interpretable
electron density map at 2.8A˚ resolution.
Density modiﬁcation and automated building was
carried out by using the program RESOLVE (43) to
produce an initial model, which was extended through a
combination of manual building in Coot (44) and reﬁne-
ment with the PHENIX suite (45). This model was then
used to solve the P21 data set by molecular replacement
using PHASER (46), which contained four molecules per
asymmetric unit, and a solvent content of 52%.
Peptides
Biotinylated peptides were purchased from Pepceuticals
Ltd, Nottingham, UK, or from the University of Bristol
Peptide Synthesis Facility, Bristol UK.
Rad9Tail: pS387, Biotin-SPVLAED[pS]EGE
H2A.1: pS129, Biotin-GSG-YSGSRTGKP-[pS]-QEL
Fluorescein-labelled peptides were purchased from
Peptide Protein Research Ltd, Fareham, UK.
Rad9, pS272: ﬂuorescein-GGSDTDSH[pS]QDLGSPE
Rad9, pT355: ﬂuorescein-GGEPSTVPG[pT]PPPKKFR
Rad9, pS375: ﬂuorescein-GGSILAPVR[pS]PQGPSPV
Rad9, pS380: ﬂuorescein-GGVRSPQGP[pS]PVLAEDS
Rad9, pS387: ﬂuorescein-GGPSPVLAED[pS]EGEG
Crb2: pT215, ﬂuorescein-GGSGQVET[pT]PTRLAT
Where [pS] or [pT] corresponds to phospho-serine or
phospho-threonine, respectively.
Co-precipitation (pull down) experiments
GST-tagged proteins. A volume of 100 ml of GST,
GST-Rad9Tail WT or S387A mutant at a concentration
of 31.5mM, was mixed with 100 ml of Glutathione
Sepharose 4 FF resin (GE Healthcare) pre-equilibrated
in buffer A: 25mM HEPES pH 7.5, 100mM NaCl,
5mM EDTA, 10mM DTT and 5% v/v glycerol, then
mixed/incubated for a period of 3 h at 4C to facilitate
protein binding.
The resin was then washed three times, with successive
applications of 1ml aliquots of buffer B: 25mM HEPES
pH 7.5, 100mM NaCl, 5mM EDTA, 10mM DTT and
5% v/v glycerol supplemented with 0.1% v/v BSA (NEB,
Hitchin, UK) and 0.1% v/v NP-40 (buffer B).
A volume of 100 ml of GST-CKIIa, at 31.5 mM, in buffer
B supplemented with 10mM ATP and 30mM MgCl2 was
added to the resin slurry, then mixed/incubated at 4C for
a period of 15 h. The resin was then washed with 1ml of
buffer B, and a further three times with 1ml aliquots of
buffer A.
Then, 100 ml of His-tagged TopBP1(1–290), at 94.5 mM
in buffer B, was added to the beads and incubated for a
further period of 3 h at 4C. The beads were then washed
four times, with 1ml aliquots of buffer A. Samples of each
co-precipitation were then analyzed by SDS–PAGE.
Dephosphorylation of immobilized GST-Rad9Tail WT,
was performed after the CK2a phosphorylation step, by
the addition of 40 mg of -phosphatase and 30U of calf
intestinal alkaline phosphatase (CIP, NEB) in 100 ml of
buffer B supplemented with 30mM MnCl2, then
incubated for 15 h at 4C.
Biotinylated peptides. A volume of 100 ml of biotinylated
Rad9Tail phospho-peptide at 140 mM, or H2A.1
phospho-peptide at 100 mM, in buffer A, was added to
100 ml of NeutrAvidin agarose beads (Thermo Fisher
Scientiﬁc, Loughborough, UK), then incubated/mixed at
4C for a period of 1 h, before being washed with three
successive 1 ml aliquots of buffer A. A volume of 100 ml of
His-tagged TopBP1(1–260), at 42 mM in buffer B, was
then added to the resin slurry and incubated for a
further period of 2 h at 4C. Samples were analysed by
SDS–PAGE, after washing the beads a further four times
with buffer A.
Dephoshorylation and re-phosphorylation steps were
carried out using -phosphatase/CIP and CKIIa as
before.
All samples were analysed by SDS–PAGE, on 4–12%
NuPAGE Bis–Tris gels (Invitrogen, Paisley, UK) run in
1MES buffer (Invitrogen). Western blots, used a mouse
anti-his primary (TaKaRa Bio, Cat No: 631212) and an
HRP-conjugated anti-mouse (GE Healthcare, Cat No:
NXA931) secondary antibody.
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Fluorescence polarization
Fluorescein-labelled peptides at a concentration of 10 nM,
were incubated at 4C, for a period of 30min with
increasing concentrations of WT or mutant
TopBP1(1–290) in 25mM HEPES pH 7.5, 100mM
NaCl, 5mM EDTA, 10mM DTT, 5% v/v glycerol,
0.01% v/v NP40. The samples (typically a volume of
50 ml) were then transferred to a black 96-well polypropyl-
ene plate (VWR, Lutterworth, UK) for measurement of
ﬂuorescence polarization in a Victor V2 Multilabel Reader
(Perkin Elmer, Cambridge, UK). Two 0.1 s measurements
were collected for each well with excitation/emission
wavelengths of 485 and 535 nm, respectively, with either
parallel or perpendicular polarizers in-line. Background
ﬂuorescence in wells containing only buffer was subtracted
from all values obtained for the samples.
Polarization data were analysed using GraphPad Prism
5.0 by non-linear ﬁtting with a one-site total binding
model. The non-speciﬁc binding component was then sub-
tracted from the data for presentation purposes. All data
represent the mean of three separate experiments, and
error bars represent one standard deviation.
RESULTS
Structure of TopBP1 N-terminus
An N-terminal construct of human TopBP1 (residues
1–290) was expressed in E. coli using a
selenomethionine-supplemented medium, and two differ-
ent crystal forms were obtained. The structure was
determined by a two-wavelength anomalous diffraction
experiment, and reﬁned at a resolution of 2.6A˚
(‘Materials and Methods’ section and Table 1).
As expected from the previous amino acid sequence
analysis (28), the crystal structure of TopBP1(1–290) con-
tained the predicted BRCT domains 1 and 2, formed by
residues 106–198 and 199–289, respectively. More
surprising was the presence of an additional undocument-
ed BRCT domain, N-terminal to these, consisting of
residues 1–105, although the possibility of this had previ-
ously been suggested (28). To maintain consistency with
published nomenclature, the second- and third-BRCT
domains in this structure will be referred to as BRCT1
and 2, while the unexpected BRCT domain at the
extreme N-terminus is designated BRCT0 (Figure 1A
and B).
Previous structural and bioinformatics analysis has
identiﬁed two sub-classes of BRCT domains, those such
as the C-terminal domain of XRCC1 (47) which occur as
singletons, and those in proteins such as BRCA1, Crb2,
53BP1, Mdc1, etc., which are involved in phospho-peptide
binding, and occur as tandem pairs, closely linked in
sequence and in 3D structure. To our knowledge, the
TopBP1(1–290) structure is the ﬁrst example of a closely
linked triple-BRCT, and is structurally distinct from the
previously described singleton and tandem examples.
Examination of the TopBP1 BRCT0:1 or BRCT1:2
pairs, reveals a very different juxtaposition of the consecu-
tive BRCT domains from each other, and from previously
documented ‘conventional’ tandem BRCT structures
(Figure 1C and D). Despite the individual BRCT
domains having a standard b1-a1-b2-b3-a2-b4-a3
topology and each having its C-terminal a3 helix con-
nected to the N-terminal b1 strand of the subsequent
BRCT, the central b-sheets in the BRCT domains are per-
pendicular to each other rather than parallel as in canon-
ical tandem BRCT structures. In the TopBP1(1–290)
structure this spatial arrangement is dictated by the very
short nature of the linkers between consecutive BRCT
domains: BRCT0 a3 helix is connected to BRCT1 b1
strand through a 17-amino acid linker (91–108) and
BRCT1 a3 helix is connected to BRCT2 b1 strand
through a 22-amino acid linker (181–203). This contrasts
with all other known tandem BRCT structures where
longer inter-domain linkers permit a more extended ar-
rangement in which the a3 helix of the upstream BRCT
domain packs against the a1 helix of the downstream
BRCT domain (Supplementary Figure S1).
Overall, the three consecutive BRCT domains form a
continuous molecular surface of roughly cylindrical shape,
with signiﬁcant burial of hydrophobic surface at the inter-
faces. Consistent with this, the overall arrangement of the
three domains seems to be rigid, and is essentially identical
Table 1. Data collection, phasing and reﬁnement statistics
Data collection
Space group P213 P1211
Cell dimensions a, b, c (A˚) 115.8, 115.8, 115.8 39.5, 290.3, 60.6
Cell angles a, b, g () 90.0, 90.0, 90.0 90.0, 89.5, 90.0
Resolution (A˚) 51.8–2.8 (2.95–2.8)* 55.9–2.6 (2.74–2.6)
Rmerge 0.091 (0.50) 0.103 (0.38)
I/sI 6.9 (1.5) 5.0 (2.0)
Completeness (%) 99.9 (99.9) 97.2 (97.2)
Redundancy 5.9 (6.1) 2.6 (2.6)
Wilson B (A˚2) 75.2 56.2
Phasing power Acentric Centric
Phasing
Se inﬂection anomalous 1.313 (0.300)
Se peak anomalous 1.377 (0.310)
Se peak isomorphous 0.123 (0.065) 0.097 (0.044)
FOM 0.3972 0.1495
Reﬁnement
Resolution (A˚) 47.3–2.80 51.3–2.60
Reﬂections (work/free) 24687/1254 76051/3850
Rwork/Rfree 0.232/0.251 0.205/0.266
Number of atoms
Protein 2280 9438
Ligands/ions 17 66
Solvent 73 343
B factors
Protein 58.7 57.5
Ligands/ions 83.7 52.8
Solvent 37.1 43.2
R.m.s.d. values
Bond lengths (A˚) 0.003 0.005
Bond angles () 0.603 0.806
Ramachandran plot (%)
Favoured 97.5 99.0
Allowed 2.5 1.0
Outliers 0.0 0.0
*Highest resolution shell is shown in parenthesis.
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in the two different crystal forms (r.m.s.d of 0.91A˚ over
279 Ca positions), which involve distinct crystal lattice
contacts.
Phospho-peptide-binding sites
Previous studies have implicated TopBP1 BRCT domains
1 and 2 in interaction with the phosphorylated tail of
Rad9 (25). Structures of tandem BRCT domains bound
to phosphopeptides (48–54), have identiﬁed a conserved
cluster of charged and polar amino acids in the
ﬁrst-BRCT domain of a tandem pair, that provide
generic interactions with the phosphorylated residue in a
phosphopeptide ligand, while residues in the cleft formed
by the junction of the two BRCT domains, furnish speci-
ﬁcity for ligand residues C-terminal to the phosphorylated
serine or threonine. Examination of the three BRCT
domains in TopBP1(1–290) shows the presence of the
Figure 1. Structure of the N-terminus of TopBP1. (A) Schematic representation of human TopBP1, highlighting the position of each BRCT domain.
The boxed region indicates the amino acid boundaries of the TopBP1(1–290) expression construct used in this study. (B) The X-ray crystal structure
of TopBP1(1–290) reveals three consecutive BRCT domains, designated as BRCT0, BRCT1 and BRCT2 (coloured grey, yellow and orange,
respectively). Amino acid boundaries of each domain are indicated in parentheses. This and all other molecular graphics ﬁgures were produced
with MacPyMOL unless otherwise stated. (C) Superimposition of the ﬁrst BRCT domain in the consecutive TopBP1 BRCT pairs BRCT0:1 and
BRCT1:2 onto the ﬁrst-BRCT domain in the canonical-tandem BRCT structure (cyan) of Crb2 in a phospho-H2A.1 peptide complex (PDB: 2VXC),
reveals signiﬁcant differences in juxtaposition of the two domains in both TopBP1 pairs (left, middle). In contrast (right), both BRCT domains in the
canonical pair from BRCA1 (pink), align with their equivalents in Crb2. The bound phospho-peptide from the Crb2–pH2A.1 complex is shown in
stick representation. In order to improve the clarity of the ﬁgure, some interconnecting loops have been omitted. (D) Comparison of the TopBP1
BRCT0:1 and BRCT1:2 pairs, based on superimposition of the outlined domain from each, but with the pairs separated for clarity, reveals distinct
and idiosyncratic domain juxtapositions for each, and the absence of any repeating poly BRCT superstructure.
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generic phospho-peptide recognition motif in BRCT
domains 1 and 2, but not in BRCT0, where the topologic-
ally equivalent residues are hydrophobic (Figure 2A). The
two putative phosphopeptide-binding patches on BRCT1
and 2 are disconnected from each other, and are arrayed
90 apart around the overall cylindrical axis of the
TopBP1(1–290) structure. The interface between BRCT1
and 2 is quite different from the more conventional
tandem BRCT structures as it does not provide the
peptide-binding cleft. Instead, the phosphopeptide-
binding patch on BRCT1 runs into a helical channel
winding around the TopBP1(1–290) structure, and
connecting to the phosphopeptide-binding patch on
BRCT2 (Figure 2B).
Phosphate-binding sites in proteins frequently show
high afﬁnity for sulphate ions, which are iso-structural
with phosphate. Crystals of TopBP1(1–290) grown in
buffers containing MgSO4 instead of the original
200mM MgCl2 displayed strong electron density for
sulphate ions bound to the putative phosphopeptide-
binding sites in BRCT1 and BRCT2 (Figure 2C), where
the key residues are conserved, but not in BRCT0, where
they are not.
Rad9 phosphorylation
The Rad9 C-terminal tail, extending beyond the structur-
ally deﬁned PCNA-like core (55–57), contains multiple
sites of phosphorylation that are conserved to varying
degrees from yeast to mammals (Supplementary
Figure S2). A conserved site, Ser272 in human Rad9,
occurs close to the N-terminus of the tail immediately fol-
lowing the PCNA-like core, and is believed to be
phosphorylated by ATM/ATR on genotoxic stress
(58,59). The opposite end of the Rad9 tail contains a
second well-conserved site, Ser387 in humans, whose
phosphorylation at least in metazoa, is constitutive and
required for TopBP1 recruitment and consequent activa-
tion of ATR as part of checkpoint signalling (6,8,10,25).
Multiple potential sites for phosphorylation by the
cyclin-dependent kinase Cdc2 (7) can also be identiﬁed
between the 272 and 387 sites, but the signiﬁcance of
these is not known.
The nature of the kinase responsible for providing the
essential TopBP1-binding site at Rad9-pSer387, has not
previously been determined, although bioinformatics
analysis (60) suggested CK2, which would certainly be
consistent with the constitutive nature of the phosphoryl-
ation. To determine whether CK2 could provide this es-
sential phosphorylation, we expressed a GST-fusion with
the C-terminus of Rad9 (GST-Rad9Tail; amino acids
264–391) in E. coli, incubated it with recombinant maize
CK2a and Mg-ATP as described earlier (61), and tested its
ability to co-precipitate TopBP1(1–290) (Figure 3A). GST
alone incubated with CK2a and Mg-ATP, or
GST-Rad9Tail incubated with CK2a in the absence of
Mg-ATP, failed to co-precipitate detectable
TopBP1(1–290). GST-Rad9Tail incubated with CK2a in
the presence of Mg-ATP gave a robust co-precipitation of
TopBP1(1–290), whereas a GST-Rad9Tail construct with
an S387A mutation incubated in the same conditions
failed to signiﬁcantly co-precipitate TopBP1(1–290). To
further test the speciﬁcity of the interaction, we repeated
the experiment with a biotinylated-synthetic peptide con-
sisting of the last 11 residues of human Rad9 with a
phosphoserine at 387. Again we observed a robust
co-precipitation of TopBP1(1–290) by neutravidin beads
in the presence of the pS387 peptide or a
dephosphorylated peptide that was incubated with CK2a
and Mg-ATP, but not with the dephosphorylated Rad9
peptide, or with an unrelated biotinylated phosphopeptide
derived from the C-terminus of S. pombe histone H2A.1
(Figure 3B). Taken together these data conﬁrm that the
Figure 2. Phosphopeptide-binding sites in TopBP1 N-terminus.
(A) Comparison of the phosphopeptide-binding site in a canonical
tandem BRCT structure, Crb2, with the topologically equivalent sites
in TopBP1 BRCT0, BRCT1 and BRCT2. The pattern of residues that
provide the phosphate interaction in Crb2 and in other known
phosphopeptide-binding BRCT domains, are present in BRCT1 and
BRCT2 but not BRCT0 where the site is hydrophobic in nature.
(B) Surface representation of TopBP1(1–290) structure coloured by
domain as in Figure 1. The conserved putative phosphopeptide-binding
patches conserved in BRCT1 and BRCT2 are highlighted in green.
(C) Difference Fourier maps from crystals of TopBP1(1–290) grown
in a buffer containing MgSO4, show signiﬁcant density (>2.5s) in
the putative phosphopeptide-binding sites of BRCT1 and BRCT2, cor-
responding to bound sulphate. This conﬁrms that both sites are com-
petent for interacting with the phosphate of a phosphopeptide.
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C-terminal sequence of Rad9 including pSer387 is essen-
tial for interaction with TopBP1(1–290) and that the key
phosphorylation is likely to be provided by CK2.
Identiﬁcation of the Rad9 interaction site in TopBP1
Previous studies in Xenopus, have implicated the
N-terminal region of TopBP1 as necessary for interaction
with the C-terminally phosphorylated Rad9 tail (25).
Within that region of TopBP1 the structural data pre-
sented here reveal three BRCT domains, two of which
(BRCT1 and BRCT2) possess the characteristic motifs
for phosphopeptide interaction, identiﬁed from studies
of conventional tandem BRCT structures (48–54,62,63).
While involvement of BRCT0 in mediating part of the
interaction with Rad9 cannot be totally ruled out, the
strong dependence of the interaction on phosphorylation
suggests that one or both of BRCT1 and BRCT2 are likely
to play the dominant role.
To test this, we generated a series of mutants, in which
key residues in the phosphopeptide interaction motifs of
BRCT1, BRCT2 or both, were changed to residues that
would be likely to abrogate phosphopeptide interaction,
based on analysis of other BRCT systems (49). We then
determined the interaction of these with a ﬂuorescently
labelled synthetic phosphopeptide incorporating the last
13 residues of human Rad9 with the equivalent of
Ser387 phosphorylated, using a ﬂuorescence polarization
(FP) assay (Figure 4A). Wild-type TopBP1(1–290) bound
the Rad9 peptide with a Kd=2.1mM. The interaction was
speciﬁc to the Rad9 sequence, and no interaction was
observed with a non-cognate ﬂuorescent phosphopeptide
derived from a segment of S. pombe Crb2, implicated in
binding to the TopBP1 homologue, Rad4 (Figure 4B).
Mutation of Thr114, Arg121 or Lys155 in the putative
phosphopeptide-binding site in BRCT1, signiﬁcantly
decreased the strength of the interaction, but did not
totally abolish it (Figure 4C). In contrast, mutation of
Thr208, Arg215 and Lys250 in BRCT2, did not weaken
the interaction, but actually caused a slight increase in
afﬁnity (Figure 4D). Double mutants, in which the
putative binding sites in both BRCT domains were dis-
rupted, showed no measurable interaction with the Rad9
phosphopeptide (Figure 4E).
The substantial loss of afﬁnity on mutation of the
BRCT1 site, clearly implicates it as the primary determin-
ant of Rad9 C-terminal phosphopeptide binding in the
TopBP1(1–290) construct. The weak-residual interaction
observed when the BRCT1 site, but not the BRCT2 are
mutated, could suggest that BRCT2 also contributes to
the interaction and that the two sites cooperate.
However the observation that binding is actually tighter
when the BRCT2 site is disabled, contradicts this inter-
pretation, and is more consistent with it displaying a weak
non-speciﬁc binding activity for the Rad9 phosphopeptide
that competes with speciﬁc binding to BRCT1 in this
assay. Together with the observation of sulphate
ion-binding this does strongly support the idea that
BRCT2 possesses a competent phosphopeptide-binding
site, but one whose speciﬁc target is something other
Figure 3. Rad9-tail phosphorylation and TopBP1 binding. (A) Pull-down assay of binding of His6-TopBP1(1–290) to a GST-Rad9 tail construct.
His6-TopBP1(1–290) was efﬁciently co-precipitated only when the GST-Rad9 tail construct was incubated with the protein kinase CK2a in the
presence of Mg-ATP, but not by GST alone, or a mutant in which the target phosphorylation site, Ser387 was changed to alanine. (B) Pull-down
assay using a synthetic biotin-coupled peptide incorporating a phosphoserine at the equivalent of Ser387. His6-TopBP1(1–290) was efﬁciently
co-precipitated by the biotin-pS387 peptide, but not by a different biotinylated-phosphopeptide, nor by the biotin-pS387 peptide treated with
phosphatase. Incubation of phosphatase-treated peptide with CK2a+MgATP restored binding.
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than the Rad9 C-terminal sequence incorporating
pSer387.
Human Rad9 has a cluster of poorly conserved putative
Cdc2 phosphorylation sites upstream of Ser387, at
Thr355, Ser375 and Ser380 (7) (Supplementary Figure
S2). The proximity of these to Ser387 in the linear
sequence of the Rad9 tail, and the physical proximity of
the BRCT1 and BRCT2 phosphopeptide-binding sites in
the TopBP1(1–290) structure suggested the possibility that
BRCT2 might provide a binding site for one of these. To
test this, we synthesized ﬂuorescently labelled
phosphopeptides incorporating pThr355, pSer375 or
pSer380, and used these in FP assays as above.
However, unlike the pSer387 peptide, neither of these
phosphopeptides showed any signiﬁcant ability to bind
to TopBP1(1–290) speciﬁcally (Figure 4F). Finally, we
Figure 4. Speciﬁcity of phospho-peptide binding to TopBP1(1–290). (A) Binding afﬁnity of TopBP1(1–290) for a ﬂuorescein-labeled Rad9-derived
peptide, incorporating pSer387, as determined by ﬂuorescence polarization. The calculated Kd (shown in parenthesis) indicates a speciﬁc interaction.
For calculation of Kd see ‘Materials and Methods’ section. (B) As (A) but with a labelled phosphopeptide derived from the S. pombe checkpoint
mediator protein Crb2. No signiﬁcant binding is observed, conﬁrming the speciﬁcity of the Rad9 interaction. C) As (A), but with TopBP1(1–290)
constructs harbouring mutations in the putative phosphopeptide-binding site in BRCT1. The afﬁnity of the interaction is substantially reduced,
indicating a signiﬁcant contribution to the interaction by BRCT1. (D) As (C), but with TopBP1(1–290) constructs harboring mutations in the
putative phosphopeptide-binding site in BRCT2. The afﬁnity of the interaction is comparable to that for wild-type TopBP1(1–290), indicating that
there is no signiﬁcant contribution to the interaction by BRCT2. (E) As (C), but with TopBP1(1–290) constructs with mutations in both putative
phosphopeptide-binding sites. The weak-residual binding present in BRCT1 mutants is effectively abolished in the double mutants. (F) As (A), but
with phosphopeptides corresponding to ﬁve different phosphorylation sites that have been mapped within the Rad9 tail. Only the peptide
incorporating pSer387 shows signiﬁcant afﬁnity.
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considered the possibility that BRCT2 might provide a
binding site for the relatively well-conserved pSer272 site
at the N-terminal end of the Rad9 tail. Again, no signiﬁ-
cant afﬁnity was observed for a ﬂuorescently labelled
pSer272 phosphopeptide.
DISCUSSION
BRCT domain architecture of TopBP1
BRCT domains are key sites of protein–protein inter-
action in the regulation and assembly of numerous
complexes involved in replication and repair of DNA
(64). From previous biochemical and structural studies
they can be roughly partitioned into two functional
classes—singleton BRCTs typically involved in mediating
homo or hetero-dimerization with other BRCT domains
(65,66), and tandem BRCTs where pairs of closely con-
tiguous BRCT domains cooperate to provide sequence
speciﬁc binding sites for (typically) phosphorylated
peptide motifs on other proteins (35). At the sequence
level, TopBP1 appears to be a composite of both types
of BRCT, with the tandem pairs BRCT1:2, BRCT4:5
and BRCT7:8 conforming to the consensus for
phosphopeptide binding, while BRCT domains 3 and 6
resemble non-phospho-binding singletons (34). The data
presented here shows the architecture of TopBP1 to be far
more complicated, with an additional BRCT domain at
the N-terminus of the protein, contributing to a complex
triple-BRCT structure that has no precedent in previously
described systems.
In light of this new data, we have re-examined the
amino acid sequence attributes of closely contiguous
tandem BRCT pairs, and ﬁnd that we can distinguish
between the ‘canonical’ phosphopeptide-binding tandem
pairs (e.g. Crb2, BRCA1, Mdc1, etc.) and the novel struc-
tural arrangements found in TopBP1, by consideration of
the size of the peptide segment that links the individual
BRCT domains. Thus, the canonical tandem BRCT struc-
tures, in which the individual domains of the pair have a
similar orientation and are effectively related by a trans-
lation, have a segment of 32–49 amino acid residues
connecting the last a-helix of the ﬁrst-BRCT domain to
the ﬁrst b-strand of the second (Figure 5A). In the novel
arrangements found in TopBP1, by contrast, these linker
segments are substantially shorter, with 17 residues con-
necting BRCT domains 0 and 1, and 22 connecting BRCT
domains 1 and 2. With the shorter linker, the juxtaposition
of the consecutive BRCT domains is highly constrained
and results in a screw relationship, with the putative
Figure 5. BRCT-domain classes in TopBP1 and other BRCT domain proteins. (A) Array of the linkers connecting consecutive BRCT domains in
structurally characterized tandem BRCT proteins. The linker segments in the triple-BRCT structure of TopBP1(1–290) are substantially shorter,
resulting in the novel non-canonical domain arrangement. (B) Assignment of BRCT domain classes in TopBP1. Domains 1, 2, 3, 5 and 7 show the
characteristics of phosphopeptide binding, but only BRCT7:8 resemble the canonical tandem pair arrangement found in checkpoint mediators such
as Crb2, BRCA1, etc.
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functional sites on consecutive BRCT domains presenting
on opposite sides of an overall cylindrical structure.
Based on this, we have re-examined the BRCT domain
structure of the rest of TopBP1 itself, and ﬁnd that
BRCT4:5, with an estimated linker length of 25 amino
acids more closely resembles the novel arrangement
found in BRCT0:1 and BRCT1:2, than the canonical
tandem arrangement. Signiﬁcantly, BRCT4 lacks the
cluster of conserved residues associated with
phosphopeptide-binding-tandem BRCT structures.
BRCT7:8 on the other hand, conforms more to a canon-
ical tandem pair, with a predicted linker of 56 amino
acids, and conservation of phospho-binding residues in
BRCT7 but not in BRCT8 (Figure 5B and Table 2).
Phosphopeptide recognition by TopBP1
The data presented here identiﬁes Rad9 Ser387 as a
probable target of CK2, that when phosphorylated, inter-
acts speciﬁcally with the N-terminal region of TopBP1 and
thereby mediates the functionally essential coupling of
TopBP1 and the 9–1–1 complex (25). The presence of
three distinct BRCT domains within TopBP1(1–290) con-
siderably complicates the previous expectation that
BRCT1:2 would constitute a canonical phosphopeptide-
binding tandem BRCT repeat of the type previously docu-
mented in BRCA1, Mdc1, 53BP1/Crb2, Nbs1, etc.
(48–54,62,63), where the ﬁrst BRCT provides the phos-
phate recognition, while the second deﬁnes the additional
sequence speciﬁcity. Instead, TopBP1 BRCT1:2 deﬁnes a
new class of tandem BRCT arrangement in which the two
consecutive domains independently offer binding sites for
phosphorylated Ser/Thr residues.
Our mutagenesis and interaction data strongly impli-
cates BRCT1 as the primary binding site for the Rad9
pSer387 motif. BRCT2, while conserving all the residues
usually involved in phosphopeptide binding, and display-
ing the characteristic afﬁnity for sulphate, only has a low
afﬁnity for the pSer387 peptide. As in other BRCT
systems, we have analysed (49), while interaction with
the phosphorylated residue provides a signiﬁcant compo-
nent of afﬁnity for the ligand peptide, there are other
overriding speciﬁcity determinants. In the canonical
tandem-BRCTs, these are furnished by the second
BRCT domain—the structural basis for this speciﬁcity in
the non-canonical TopBP1 BRCT1:2 structure is still to be
deﬁned.
The tail of Rad9 provides a site for multiple phosphor-
ylations in yeasts and in animals, although the location
and genesis of these vary amongst different organisms.
For example, the extreme C-terminal sites (Thr412/
Ser423) in S. pombe Rad9 are modiﬁed by ATR (Rad3)
and/or ATM (Tel1) in response to cell-cycle progression
and/or DNA damage, whereas the equivalent C-terminal
site (Ser387) in mammals is constitutively modiﬁed,
probably by CK2 as we have shown here. In both cases
however, these phosphorylations are essential for
mediating the physical coupling of Rad9 to
TopBP1(Rad4), that functionally connects the 9–1–1 and
ATR (Rad3) complexes. Metazoan Rad9 does possess an
ATR/ATM damage regulated phosphorylation site
(Ser272), but at the N-terminal end of the tail segment
close to the PCNA core, and several cell cycle-regulated
CDK phosphorylation sites have also been mapped
upstream of the TopBP1-binding pSer387. Despite the
presence of multiple phosphorylation sites on Rad9,
only phosphopeptides containing the pSer387 site shows
the level of afﬁnity for the TopBP1 BRCT0:1:2 segment,
that is consistent with a biologically signiﬁcant inter-
action, and while some small involvement of BRCT
domains 0 and 2 in that interaction cannot be totally
ruled out, the interaction with BRCT1 alone seems both
necessary and sufﬁcient. What protein–protein inter-
actions are mediated by the other phosphorylation sites
on Rad9, or by the BRCT0 and BRCT2 domains of
TopBP1 remain to be deﬁned. Experiments to address
this are in progress.
During the preparation and review of this article, add-
itional evidence supporting the role of CK2 in mediating
the 9-1-1—TopBP1 interaction was published by Takeishi
et al. (67); demonstrating that residues Ser341 and Ser387
are both in vitro targets of the kinase, are phosphorylated
in vivo, and that HeLa cells over-expressing a
phospho-deﬁcient form of Rad9 display hypersensitivity
to both UV and methyl methane sulphonate (MMS)
treatment.
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Table 2. Phospho-binding analysis of TopBP1 BRCT domains
Phospho binding
Crb2 (1) Arg558 Ser548 Lys619 Yes
BRCT0 Phe68 Leu14 Val67 No
BRCT1 Arg121 Thr114 Lys155 Yes
BRCT2 Arg215 Thr208 Lys250 Yes
BRCT3 Leu374 Cys367 Glu407 No
BRCT4 Glu568 Leu561 Glu602 No
BRCT5 Lys661 Ser654 Lys704 Yes
BRCT6 Gln920 Val912 Glu957 No
BRCT7 Arg1280 Ser1273 Lys1317 Yes
BRCT8 Glu1408 His1402 Asn1452 No
Amino acids at the topologically equivalent positions associated with
binding the phospho-group of phosphorylated peptides in a canonical
phospho-binding BRCT domain (Crb-BRCT1), are conserved in
TopBP1 BRCT domains 1, 2, 5 and 7.
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